April 6, 2023
Nippon Kayaku’s Avastin (bevacizumab) biosimilar won approval in Japan to add an additional indication of ovarian cancer, the company and its partner Celltrion Healthcare Japan said on April 5. The Bevacizumab BS IV Infusion 100 mg/400 mg “CTNK” was launched...read more